ADC Therapeutics sets terms for $125m IPO

Businessmen trading stocks online. Stock brokers looking at graphs, indexes and numbers on multiple computer screens. Colleagues in discussion in traders office. Business success concept.

Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop its pipeline of antibody-drug conjugate drugs as they head towards regulatory review. 

As its name suggests the Lausanne-based firm, with operations in London, San Francisco Bay and New Jersey, works on drugs based on antibodies that target cancerand deliver a payload that kills the malignant cells, while leaving healthy tissue intact. 

The IPO has launched with 7,355,000 common shares, and the underwriters have an option to buy a further 1.1 million common shares.

Shares are expected to be valued at between $16 and $18 each and have been approved for listing on the New York Stock Exchange under the ticker symbol "ADCT".

The company's lead product loncastuximab tesirine – known as Lonca for short or by its old codename of ADCT-402 – has been evaluated in a 145-patient pivotal phase 2 clinical trial for relapsed or refractory diffuse B-cell lymphoma. 

It showed a 45.5% interim overall response rate, which exceeded the target primary endpoint. 

The antibody part of the drug targets CD-19 – the same target used for the first generation of CAR-T therapies. 

With the kind of response rates seen so far in clinical trials it’s anticipated that the ADC could compete against CAR-T drugs, without the cumbersome and costly manufacturing process used to create cell therapies. 

Its second lead product candidate camidanlumab tesirine – known as cami or ADCT-301 – is being tested in a 100-patient pivotal phase 2 trial for relapsed or refractory Hodgkin lymphoma. 

Developed in partnership with Genmab, Cami produced an overall response rate of 86.5% in a phase 1 trial in Hodgkin lymphoma. 

ADC Therapeutics is also testing Cami as a novel immuno-oncology therapy for various advanced solid tumours. 

The antibody part of the drug targets CD25, while the cancer-killing payload is a proprietary and highly potent pyrrolobenzodiazepine (PBD) molecule. 

Its pipeline also includes a phase 1 ADC, targeting various solid tumours with an AXL mutation. 

ADC Therapeutics raised $200 million in late 2017 on the back of some eye-catching phase 1 data from the two drugs. 

At that time the total funding raised by the company was $455 million to finance the company’s pivotal trials.